CFO
LGND icon

Callan Family Office’s Ligand Pharmaceuticals LGND Stock Holding History

Callan Family Office’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
3,224
+21
+0.7% +$4.95K 0.02% 594
2026
Q1 		$639K Buy
3,203
+17
+0.5% +$3.36K 0.01% 687
2025
Q4 		$602K Buy
3,186
+321
+11% +$61.7K 0.01% 715
2025
Q3 		$508K Buy
2,865
+1
+0% +$149 0.02% 530
2025
Q2 		$326K Buy
2,864
+426
+17% +$45.5K 0.01% 742
2025
Q1 		$256K Hold
2,438
– – 0.02% 464
2024
Q4 		$261K Buy
+2,438
New +$276K 0.02% 529

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Callan Family Office's LGND Position: Q2 2026 in Review

Callan Family Office increased its Ligand Pharmaceuticals (LGND) stake by 0.66% in Q2 2026, buying an estimated $4.95K and bringing the position to 3,224 shares worth $1.02M. The position accounts for 0.02% of the portfolio, ranked #594.

Callan Family Office first reported a position in LGND in Q4 2024 and has held it in 7 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Callan Family Office held 3,224 shares of Ligand Pharmaceuticals worth $1.02M as of Q2 2026.
  • Callan Family Office bought 21 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.95K.
  • Ligand Pharmaceuticals made up 0.02% of Callan Family Office's portfolio in Q2 2026, its #594 holding.
  • Callan Family Office first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.